Albumin-based nanodevices for breast cancer diagnosis and therapy

Yue Wang,Haroon Iqbal,Uzair Ur-Rehman,Lina Zhai,Ziyin Yuan,Anam Razzaq,Man Lv,Huiying Wei,Xin Ning,Jun Xin,Run Xiao
DOI: https://doi.org/10.1016/j.jddst.2022.104072
IF: 5
2022-12-11
Journal of Drug Delivery Science and Technology
Abstract:Since, after the successful approval of albumin-based nanodrug "Abraxane" by food and drug administration (FDA) in 2005, considerable interests have been gained by protein-based nanoparticles in the field nanomedicine for cancer therapy. In recent years, various protein-based nanodevices have been developed; amid them, serum albumin as an intrinsic constituent of blood with no immunogenicity and toxicity regarded as an ideal tool to cargo and deliver diagnostic and therapeutic modalities to breast cancer cells simultaneously, named as theranostic. Serum albumin-based nanodevices are commonly loaded or conjugated with near infrared (NIR dyes), contrast agents, radionuclides, photosensitizers and organic or inorganic nanoclusters and chemotherapeutic agents. In general, serum albumin nanodevices offer several advantages such as biocompatibility, biodegradability, prolonged blood circulation, escape clearance by macrophages and surface modification with drugs or targeted ligand. Moreover, it can be easily prepared without using any toxic organic solvent or chemical agents. In addition, the nanoscale size of devices also facilitates the deep penetration into tumor tissue. This mini-review embodies general overview of albumin and its properties, tumor targeting mechanism and designed formulations, along with their applications in breast cancer diagnosis and therapy from the recent literature. Finally, the current challenges and future perspective are identified for translating serum albumin-based nanodevices from laboratory to clinical application. Graphical abstract Download : Download high-res image (218KB) Download : Download full-size image
pharmacology & pharmacy
What problem does this paper attempt to address?